UK markets close in 6 hours 43 minutes

Immunicum AB (publ) (IMMU.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
3.1200-0.0800 (-2.50%)
As of 10:40AM CET. Market open.
Full screen
Previous close3.2000
Open3.1900
Bid3.0950 x 0
Ask3.1200 x 0
Day's range3.0950 - 3.2000
52-week range2.7050 - 7.8750
Volume26,896
Avg. volume804,896
Market cap622.131M
Beta (5Y monthly)0.54
PE ratio (TTM)N/A
EPS (TTM)-0.9550
Earnings date17 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.50
  • Globe Newswire

    Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics

    Press Release Stockholm, Sweden, January 5, 2022 Immunicum Transfers Patent Rights for Modified Adenovirus to Elicera Therapeutics Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, today announced to transfer the ownership of patent US 9,017,672 B2 to Elicera Therapeutics AB. The patent is currently out-licensed to Elicera and covers a modified adenovirus that improves gene delivery and tumor

  • Globe Newswire

    Immunicum to Participate in Upcoming Investor and Industry Conferences in January

    Press Release Stockholm, Sweden, January 3, 2022 Immunicum to Participate in Upcoming Investor and Industry Conferences in January Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, today announced its participation in the following upcoming investor and industry conferences in January: H.C. Wainwright Bioconnect Virtual Conference, January 10 – 13, 2022 Erik Manting, Chief Executive Officer,

  • Globe Newswire

    Immunicum Publishes Year-End Letter by CEO and Announces Upcoming Shareholder Event to Present Pipeline Outlook

    Press Release Stockholm, Sweden, December 21, 2021 Immunicum Publishes Year-End Letter by CEO and Announces Upcoming Shareholder Event to Present Pipeline Outlook Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and the prevention of cancer recurrence, published today a year-end letter by its CEO Erik Manting addressing Immunicum’s stakeholders. The company also announced an upcoming shareholder event to present its pipeline outloo